Source review date: 20 September 2026. This is not the date of the news publication or scientific confirmation.
What period does the news concern?
In a report dated 24 July 2024, the NCI explained that on 14 May of the same year, the FDA expanded the use of two HPV tests for vaginal samples self-collected by individuals in a health-care setting. This article reviews that event; it is not an announcement of the latest authorizations or the current status of all kits.
What changed?
For some people who find a pelvic examination difficult or do not want one, self-collection can make access to screening easier. The sample is examined in a laboratory; a person does not diagnose themselves at home by looking at the sample.
Is it the same as a Pap smear?
No. This sample is used to test for HPV with the relevant validated system; a Pap smear examines cellular changes. A positive result may require a medical visit and further evaluation.
Limitations and actual use
The authorization described in the 2024 report was limited to a health-care setting. It cannot be generalized to every swab, every testing method, or every type of home sample collection. Approval of a product in the United States does not establish that it is authorized or available in Iran. Coordinate with your physician and laboratory regarding the appropriate method, collection device, and follow-up of the result.
Source and level of evidence
This is an official report about a specific change in authorization, not a claim to treat HPV or eliminate the need for follow-up.